Skip to main content

Table 4 Change in parameters between baseline and 6-months follow-up. Change in parameters that are associated with JIA (paediatric rheumatologist) and uveitis (ophthalmologist) and patient reported outcome measures from baseline to 6-months follow-up (bold highlighted beta/ OR were statistically significant)

From: Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC)

 

Baseline

3-months follow-up

6-months follow-up

Change between Baseline and 3-months follow-up

Change between Baseline and 6-months follow-up

Change between 3-months and 6-months follow-up

Effect Size

Baseline to 6-months follow-up

n; mean (sd), median

n; mean (sd), median

n; mean (sd), median

beta/ OR p value 95% CI

beta/ OR p value 95% CI

beta/ OR p value 95% CI

n(%)a

n(%)a

n(%)a

    
 

Analyses on patient level

    
 

n = 82

n = 77

n = 64

    

Pediatric rheumatologist

 Physician’s global about JIA disease activity, VAS, 0–100

71; 34.0 (28.7); 30

64; 17.0 (22.6); 10

57; 13.4 (22.4); 5

−17.7 < 0.001–23.29; −12.14

−20.2 < 0.001–26.09; −14.41

−2.5 0.401–8.46; 3.38

0.66

 Number of joints with active arthritis

83; 0.6 (1.5); 0

77; 0.4 (1.5); 0

64; 0.9 (3.8); 0

−0.1 0.636–0.77; 0.47

0.3 0.313–0.32; 1.00

0.5 0.152–0.18; 1.15

0.10

Patients reported outcomes

 Overall well-being; VAS; 0–100

47; 34.1 (29.7); 26

43; 23.5 (20.3); 20

30; 23.2 (22.3); 12

−10.5 0.003–17.48; −3.62

−13.1 0.001–20.93; −5.27

− 2.6 0.524–10.39; 5.29

0.41

 C-HAQ, 0–3

35; 0.81 (1.04); 0.5

27; 0.69 (0.88); 0.5

18; 0.52 (0.59); 0.44

− 0.2 0.056–0.45; 0.01

− 0.3 0.014–0.61; − 0.07

−0.1 0.4–0.39; 0.16

0.13

 PedsQL, 0–100

52; 78.7 (21.5); 87.8

40; 81.7 (17.9); 86.9

26; 85.5 (13.5); 89.7

3.8 0.088–0.57; 8.21

7.2 0.006 2.08; 12.30

3.4 0.201–1.80; 8.54

0.15

 Number of days in hospital due to uveitis

40; 1.9 (6.0); 0

32; 0.7 (2.7); 0

19; 1.1 (4.2); 0

−1.2 0.274–3.33; 0.94

−0.7 0.561–3.26; 1.77

0.4 0.736–2.16; 3.06

0.25

 Missed days in kindergarden/ school due to uveitis

51; 4.8 (6.7); 1

47; 3.2 (9.2); 0

32; 0.5 (1.6); 0

−1.7 0.211–4.30; 0.95

−4.3 0.004–7.25; − 1.34

−2.6 0.085–5.61; 0.37

0.20

 Number of days with restrictions in daily life due to uveitis

39; 7.4 (16.9); 0

32; 1.7 (4.8); 0

19; 5.0 (10.6); 0

−5.9 0.037–11.40; − 0.36

−2.7 0.417–9.25; 3.83

3.2 0.355–3.55; 9.90

0.44

 

Analyses on eye level

    
 

n = 147

n = 132

n = 103

    

Ophthalmologist

 Physician’s global about disease activity in the eyes, VAS, 0–100

113; 45.2 (33.9); 50

111; 30.6 (33.5); 20

87; 25.2 (32.3); 14

−15.0 < 0.001–19.13; − 10.83

−20.0 < 0.001–24.57; − 15.44

− 5.0 0.029–9.55; − 0.51

0.43

 Total number of AC cells

46; 7.4 (6.4); 7.5

28; 1.4 (3.2); 0

33; 1.9 (4.8); 0

−4.9 < 0.001–6.99; − 2.79

− 5.0 < 0.001–7.03; − 2.91

−0.1 0.942–2.29; 2.12

1.10

 Visual acuity, logMAR

119; 0.48 (0.51); 0.3

101; 0.39 (0.50); 0.1

86; 0.42 (0.52); 0.11

−0.1 0.015–0.11; − 0.01

−0.1 0.062–0.10; 0.00

0.0 0.727–0.04; 0.06

0.18

 AC cell grade

136; 2.81 (1.25); 3

116; 1.81 (1.20); 1

93; 1.39 (0.82); 1

−1.0 < 0.001–1.26; − 0.80

−1.5 < 0.001–1.72; − 1.22

−0.4 0.001–0.69; − 0.19

0.81

 AC flare grade (no flare versus flare), SUN

99 (70.2%)

49 (38.6%)

24 (25.3%)

0.1 < 0.001 0.03; 0.21

0.0 < 0.001 0.01; 0.08

0.3 0.006 0.12; 0.71

0.67

 AC flare grade (no flare versus flare), MIWGUC

53 (61.6%)

31 (37.4%)

17 (25.8%)

0.1 < 0.001 0.03; 0.34

0.0 < 0.001 0.01; 0.14

0.3 0.032 0.09; 0.90

0.50

 Any structural complications

81 (56.3%)

73 (56.2%)

64 (62.1%)

0.9 0.867 0.27; 2.99

1.1 0.904 0.28; 4.28

1.2 0.79 0.30; 4.77

0.01

 Ocular hypotony

3 (2.1%)

3 (2.4%)

0 (0.0%)

b

b

b

0.02

 Ocular hypertension

6 (4.3%)

8 (6.5%)

4 (4.1%)

6.2 0.235 0.31; 124.32

0.2 0.321 0.01; 4.05

0.0 0.109 0.00; 2.06

0.09

 Posterior synechiae

60 (43.2%)

60 (46.2%)

53 (52.0%)

5.7 0.23 0.33; 96.67

4.7 0.324 0.21; 104.42

0.8 0.903 0.05; 15.33

0.06

 Glaucoma

6 (4.4%)

6 (5.1%)

5 (5.4%)

b

b

b

0.03

 Cataract

28 (19.9%)

23 (18.3%)

24 (23.5%)

b

b

b

0.04

 Band keratopathy

31 (21.5%)

31 (24.6%)

27 (26.7%)

25.6 0.067 0.80; 826.75

14.8 0.132 0.44; 493.90

0.6 0.716 0.03; 11.13

0.07

 Optic disc edema

10 (10.9%)

6 (7.0%)

3 (4.8%)

b

b

b

0.11

 Macular edema (Funduscopy)

9 (7.0%)

4 (5.0%)

2 (2.9%)

0.3 0.288 0.04; 2.68

0.2 0.195 0.02; 2.14

0.7 0.811 0.06; 9.42

0.07

 Macular edema (OCT)

14 (21.5%)

4 (12.5%)

2 (6.1%)

b

b

b

0.08

 Epiretinal membrane formation (Funduscopy)

7 (5.5%)

7 (8.5%)

4 (5.9%)

b

b

b

0.12

 Epiretinal membrane formation (OCT)

7 (11.3%)

7 (17.5%)

5 (14.3%)

b

b

b

0.11

 Vitreous haze (yes/no)

15 (16.3%)

15 (18.3%)

13 (19.1%)

1.6 0.518 0.38; 6.97

1.5 0.632 0.31; 6.75

0.9 0.89 0.20; 4.11

0.06

 Other complications

12 (12.8%)

2 (2.4%)

0 (0.0%)

b

b

b

0.10

  1. beta regression coefficient for continuously distributed variables, CI confidence interval, n number of patients with valid assessment in the reported parameter, OR Odds ratio for categorical variables, sd standard deviation
  2. apercentages refer to the number of patients or eyes with valid assessments in the considered parameter
  3. bnot estimable due to the low number of complications